Drug-induced weight gain in the last 10 years: a descriptive study.

IF 1.5 4区 医学 Q4 CHEMISTRY, MEDICINAL Pharmazie Pub Date : 2022-10-01 DOI:10.1691/ph.2022.2408
N J Ahmed, A M Alshehri, Z S Almalki, A Alahmari
{"title":"Drug-induced weight gain in the last 10 years: a descriptive study.","authors":"N J Ahmed,&nbsp;A M Alshehri,&nbsp;Z S Almalki,&nbsp;A Alahmari","doi":"10.1691/ph.2022.2408","DOIUrl":null,"url":null,"abstract":"<p><p>Medication-induced weight gain can be frustrating to patients and health care providers. Drug-induced weight gain is a profound side effect of numerous commonly used medications. The present study aimed to investigate FAERS reports about drug-induced weight gain in the last ten years. Using the US FDA Adverse Event Reporting System (FAERS) between 2012 and 2021, a retrospective, descriptive analysis was conducted to analyze the major reported Adverse Events about weight gain. During the last ten years, 137370 reports were submitted to FAERS about drug-induced weight gain. The most common drugs that are reported by the patients and that are associated with weight gain were risperidone (11.55%), adalimumab (3.94%), pregabalin (3.86%), aripiprazole (3.1%), etanercept (2.72%), and prednisone (2.70%). In conclusion, the present study showed that drug-induced weight gain is a common side effect of several medications frequently used to treat chronic diseases. Healthcare providers should educate their patients about the medicines that may cause weight gain.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"77 10","pages":"299-301"},"PeriodicalIF":1.5000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1691/ph.2022.2408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 2

Abstract

Medication-induced weight gain can be frustrating to patients and health care providers. Drug-induced weight gain is a profound side effect of numerous commonly used medications. The present study aimed to investigate FAERS reports about drug-induced weight gain in the last ten years. Using the US FDA Adverse Event Reporting System (FAERS) between 2012 and 2021, a retrospective, descriptive analysis was conducted to analyze the major reported Adverse Events about weight gain. During the last ten years, 137370 reports were submitted to FAERS about drug-induced weight gain. The most common drugs that are reported by the patients and that are associated with weight gain were risperidone (11.55%), adalimumab (3.94%), pregabalin (3.86%), aripiprazole (3.1%), etanercept (2.72%), and prednisone (2.70%). In conclusion, the present study showed that drug-induced weight gain is a common side effect of several medications frequently used to treat chronic diseases. Healthcare providers should educate their patients about the medicines that may cause weight gain.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
最近10年药物引起的体重增加:一项描述性研究。
药物引起的体重增加可能会让患者和医疗保健提供者感到沮丧。药物引起的体重增加是许多常用药物的严重副作用。本研究旨在调查近十年来FAERS报告的药物引起的体重增加。使用美国FDA不良事件报告系统(FAERS),对2012年至2021年期间报告的与体重增加有关的主要不良事件进行回顾性描述性分析。在过去十年中,向FAERS提交了137370份关于药物引起的体重增加的报告。患者报告的与体重增加相关的最常见药物为利培酮(11.55%)、阿达木单抗(3.94%)、普瑞巴林(3.86%)、阿立哌唑(3.1%)、依那西普(2.72%)和泼尼松(2.70%)。总之,目前的研究表明,药物引起的体重增加是几种经常用于治疗慢性疾病的药物的常见副作用。医疗保健提供者应该教育他们的病人关于可能导致体重增加的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmazie
Pharmazie 医学-化学综合
CiteScore
3.10
自引率
0.00%
发文量
56
审稿时长
1.2 months
期刊介绍: The journal DiePharmazie publishs reviews, experimental studies, letters to the editor, as well as book reviews. The following fields of pharmacy are covered: Pharmaceutical and medicinal chemistry; Pharmaceutical analysis and drug control; Pharmaceutical technolgy; Biopharmacy (biopharmaceutics, pharmacokinetics, biotransformation); Experimental and clinical pharmacology; Pharmaceutical biology (pharmacognosy); Clinical pharmacy; History of pharmacy.
期刊最新文献
Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort. Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids. Cross-reactivity of triptans and sulfonamide antibiotics - a clinically relevant question? Impact of medication reconciliation and medication reviews on the incidence of preventable adverse drug reactions during hospitalization of elderly patients. A randomized controlled trial. Potential effects of attention deficit hyperactivity disorder medication on body height and body weight in a longitudinal pediatric cohort study, the LIFE Child study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1